BTLA 분자 정보
Molecule Name
B- and T-lymphocyte attenuator
분자 별명
BTLA,CD272
Drug Development Progress
임상 약물 수6
시판 약물 수0
최고 연구 개발 단계Phase 3 Clinical
표적 별명
BTLA，B- and T-lymphocyte attenuator，B- and T-lymphocyte-associated protein，B And T Lymphocyte Associated，CD272 Antigen，BTLA1，CD272
분자 배경
B- and T-lymphocyte attenuator (BTLA) is also known as B- and T-lymphocyte-associated protein, CD antigen CD272. BTLA contains one Ig-like V-type (immunoglobulin-like) domain. As a lymphocyte inhibitory receptor, BTLA / CD272 inhibits lymphocytes during immune response. BTLA / CD272 can interact with tyrosine phosphatases PTPN6/SHP-1 and PTPN11/SHP-2, and interact with TNFRSF14/HVEM.
BTLA 제품 목록
You Have Viewed 0 Of 0 Results
임상 약물 정보
| 영어 이름 | 연구 코드 | 연구 개발 단계 | 회사 | 적응증 | 임상 시험 |
|---|---|---|---|---|---|
| Tifcemalimab | JS-004; TAB-004 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Carcinoma, Renal Cell; Carcinoma, Transitional Cell; Esophageal Squamous Cell Carcinoma; Head and Neck Neoplasms; Hodgkin Disease; Lung Neoplasms; Lymphoma; Melanoma; Nasopharyngeal Carcinoma; Neoplasms; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Solid tumours; Squamous Cell Carcinoma of Head and Neck; Triple Negative Breast Neoplasms | 상세 |
| MB-272 | MB272; GS-0272 | Phase 1 Clinical | MiroBio Ltd, University Of Oxford | Arthritis, Rheumatoid; Autoimmune Diseases | 상세 |
| ANB-032 | ANB-032 | Phase 1 Clinical | Anaptysbio Inc | Dermatitis, Atopic; Eczema; Inflammation | 상세 |
| Venanprubart | LY-3361237 | Phase 1 Clinical | Eli Lilly And Company, Sanford-Burnham Medical Research Institute | Lupus Erythematosus, Systemic; Psoriasis; Sjogren's Syndrome | 상세 |
| HFB200604 AID | HFB-200604-AID; HFB200604; HFB-200604; HFB200604 AID | Phase 1 Clinical | HiFiBiO Therapeutics | Autoimmune Diseases; Inflammation | 상세 |
| HFB-200603 | HFB-200603 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Colorectal Neoplasms; Melanoma; Neoplasms; Stomach Neoplasms | 상세 |